SECOND-LINE相关论文
...
Objective: Several studies have demonstrated different benefits for patients whose disease progressed despite previous t......
Second-line panitumumab as a triweekly dose for patients with wild-typeKRAS exon 2 metastatic colore
Objective: Panitumumab administered as monotherapy in colorectal cancer (CRC) has shown response and disease stabilizati......
Clinical efficacy and safety of second line and salvage aflibercept for advanced colorectal cancer i
BACKGROUND Angiogenesis inhibitors(AIs)combination with cytotoxic chemotherapy is a promising treatment for patients wit......
Pancreatic cancer is considered one of the most aggressive cancers,with an increasing incidence in recent years.To date,......
Beyond first-line chemotherapy for advanced pancreatic cancer:An expanding array of therapeutic opti
While an increasing number of therapeutic options are now available for the first-line treatment of locally advanced or ......
幽门螺杆菌（Hp）的治疗是临床较为棘手的问题，标准三联疗法的根除率已降至80％或更低，其疗效下降可能与Hp耐药株日益增多相关。合铋四联疗......
目的：比较拓扑替康联合顺铂方案与IEP方案治疗复发性小细胞肺癌的疗效和不良反应。方法：80例复发性小细胞肺癌中,37例应用拓扑替康-D......
瞄准：与先进或变形的胰腺的癌症在 gemcitabine-pretreated 病人调查第二线的化疗[(频率，反应，结果，糖类抗原 19-9 (CA 19-9 ) 的路线]......
Second-line therapy for advanced colorectal cancer is an integral part of the treatment strategy that needs to be set fr......
Helicobacter pylori(H.pylori)is a prevalent,worldwide,chronic infection.Choice of treatment can be modified according to......
Efficacy of 14-d vs 7-d moxifloxacin-based triple regimens for second-line Helicobacter pylori eradi
AIM: To evaluate the efficacy of the 14-d moxifloxacinbased triple therapy for the second-line eradication of Helicobact......
Advanced gastric cancer(a GC), not amenable to curative surgery, is still a burdensome illness tormenting afflicted pati......
目的比较阿帕替尼与替吉奥二线治疗晚期肝细胞癌的临床效果和不良反应。方法选取85例经一线治疗失败的晚期肝细胞癌患者,采用随机......
目的:评价单药多西他赛(泰素帝)作为二线化疗对晚期非小细胞肺癌(NSCLC)的疗效和不良反应.方法:23例经病理和(或)细胞学诊断的晚期......
背景与目的：小细胞肺癌（small cell lung cancer,SCLC）一线化疗疗效较好,然而一旦复发,治疗十分困难,目前尚未确定最佳二线化疗方案。......
Efficacy and Safety of Generic Dasatinib as a Second-line Treatment for Patients with Chronic Myeloi
Dasatinib is a second-generation tyrosine kinase inhibitor (TKI)and it could be used as a second-line treatment for pati......
Safety and Efficacy of Racotumomab-Alum Vaccine as Second-Line Therapy for Advanced Non-Small Cell L
Despite extensive clinical research in non-small cell lung cancer (NSCLC), overall survival is still poor. Racotumomab-a......
目的：回顾性分析两种不同化疗方案对一线化疗失败的晚期胃癌患者进行解救治疗的疗效和安全性，探讨晚期胃癌二线治疗适宜的化疗方案。......
目的探讨雷替曲塞单药二线治疗老年晚期结直肠癌的疗效和安全性。方法将57例老年晚期结直肠癌患者随机分为试验组（29例）和对照组（28例......
Efficacy and Tolerability of Second-Line Metronidazole Triple Therapy Using Vonoprazan for Helicobac
Aim: To investigate the efficacy and tolerability of second-line metronidazole triple therapy with vonoprazan (VPZ) for ......
Raltitrexed + irinotecan as second-line chemotherapy in elderly patients with advanced colorectal ca
Aims and Background: Irinotecan is a standard option for relapsed/refractory advanced colo- rectal cancer. Combination w......
Triplet chemotherapy with paclitaxel, gemcitabine, and cisplatin as second-line therapy for advanced
Background: Methotrexate, vinblastine, doxorubicin, and cisplatin regimen, and gemcitabine and cisplatin regimen are wid......
Background: Bevacizumab-based chemotherapy has been shown to extend progression-free survival (PFS) of lung cancer, but ......
目的明确耐多药结核杆菌对部分二线抗结核药物的敏感性,为治愈耐多药结核病提供依据。方法选用改良罗氏培养基,采用药敏比例法测定......
Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancrea
BACKGROUND There is no standard therapy for second-line treatment of gemcitabine-refractory pancreatic cancer patients w......
Fourteen- vs seven-day bismuth-based quadruple therapyfor second-line Helicobacter pylori eradicatio
AIM To compare the efficacy of 14- and 7-d bismuthbasedquadruple therapies as second-line eradicationtreatment for Helic......
Gastric cancer remains one among the leading causes of cancer-related deaths, regardless of its decreasing incidence and......
AIM To evaluate the efficacy and safety of the modified FOLFIRI3-aflibercept as second-line therapy in patients with met......
Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in meta
BACKGROUND The treatment of metastatic colorectal cancer (mCRC) relies of chemotherapy. The efficacy of the standard FOL......
Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progr
Continuous inhibition of angiogenesis beyond progression is an emerging treatment concept in the management of metastati......
Objective:Several studies have demonstrated different benefits for patients whose disease progressed despite previous tr......
Over the past ten years,sorafenib,a multikinase inhibitor,has been the standard of care for patients with unresectable h......
